A recent study on BMs from ALK-rearranged NSCLC (205) has reported that crizotinib was associated with more than 55% disease control within the CNS at 3 months of therapy in both RT-naïve and RT-pretreated patients; moreover, crizotinib was associated with a moderate (18–33%) RECIST-confirmed response rate. Here, ALK is linked to non-small cell lung carcinoma.